Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome

Can a placebo produce measurable symptom change when patients are explicitly told it contains no active ingredient?

• 80 adults with irritable bowel syndrome, recruited at a single academic medical centre.
• Three-week randomized trial with two arms: open-label placebo plus the usual patient–clinician interaction, or that same interaction with no pills.
• Placebo bottles were labelled as placebo. Participants were told placebos had been shown in research to produce significant improvement through mind–body self-healing processes, and that taking the pills faithfully was important.
• Primary outcome was the IBS Global Improvement Scale; secondary outcomes covered symptom severity, relief and quality of life.

• The open-label placebo group reported higher global improvement scores than the no-treatment control at both the midpoint and endpoint of the trial.
• Differences also appeared on symptom severity and adequate-relief measures.
• The authors framed the result as a proof of concept, not a treatment recommendation.

• Small sample at a single site, with a three-week window and no long-term follow-up.
• The comparison arm received no pills at all, so ritual, attention and expectation effects cannot be separated from the pill itself.
• Outcomes were patient-reported and subjective, which is typical of IBS research but limits how far the finding generalises.

This is the reference point almost every later open-label placebo paper argues with. It reframed the question from “does deception make placebos work?” to “what part of the therapeutic encounter is doing the work?” — which is why non-deceptive placebo products exist as a research category at all.